Tango Therapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
Tango Therapeutics, Inc. (TNGX) reported Marketable Securities, Unrealized Gain (Loss) of -$518.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-11
- Tango Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$518.00K.
- Tango Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$339.00K.
- Tango Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was $103.00K.
- Tango Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $27.00K, a 97.51% decline year-over-year.
- Tango Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2025 was -$112.00K, a 174.67% decline from fiscal 2024.
- Tango Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2024 was $150.00K, a 96.14% decline from fiscal 2023.
- Tango Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was $3.89M.
- Tango Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was -$2.94M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$518.00K 10-Q · filed 2026-08-11 | -$857.00K 10-Q · filed 2026-08-11 | -$754.00K derived: sum of 3 quarters · filed 2026-08-11 | -$727.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$339.00K 10-Q · filed 2026-05-13 | -$236.00K derived: sum of 2 quarters · filed 2026-05-13 | -$209.00K derived: sum of 3 quarters · filed 2026-05-13 | -$309.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $130.00K derived: sum of 2 quarters · filed 2026-03-05 | $30.00K derived: sum of 3 quarters · filed 2026-08-11 | -$112.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $27.00K 10-Q · filed 2025-11-04 | -$73.00K derived: sum of 2 quarters · filed 2026-08-11 | -$215.00K 10-Q · filed 2025-11-04 | -$629.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$100.00K 10-Q · filed 2026-08-11 | -$242.00K 10-Q · filed 2026-08-11 | -$656.00K derived: sum of 3 quarters · filed 2026-08-11 | $428.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$142.00K 10-Q · filed 2026-05-13 | -$556.00K derived: sum of 2 quarters · filed 2026-05-13 | $528.00K derived: sum of 3 quarters · filed 2026-05-13 | $451.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$414.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $670.00K derived: sum of 2 quarters · filed 2026-03-05 | $593.00K derived: sum of 3 quarters · filed 2026-03-05 | $150.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.08M 10-Q · filed 2025-11-04 | $1.01M derived: sum of 2 quarters · filed 2025-11-04 | $564.00K 10-Q · filed 2025-11-04 | $1.43M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | -$77.00K 10-Q · filed 2025-08-05 | -$520.00K 10-Q · filed 2025-08-05 | $347.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.18M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | -$443.00K 10-Q · filed 2025-05-12 | $424.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.26M derived: sum of 3 quarters · filed 2026-03-05 | $1.94M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $867.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.70M derived: sum of 2 quarters · filed 2026-03-05 | $2.39M derived: sum of 3 quarters · filed 2026-03-05 | $3.89M 10-K · filed 2026-03-05 |
| 2023-09-30 | $836.00K 10-Q · filed 2024-11-06 | $1.52M derived: sum of 2 quarters · filed 2024-11-06 | $3.02M 10-Q · filed 2024-11-06 | $4.17M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $684.00K 10-Q · filed 2024-08-07 | $2.19M 10-Q · filed 2024-08-07 | $3.34M derived: sum of 3 quarters · filed 2025-02-27 | $2.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-08 | $2.65M derived: sum of 2 quarters · filed 2025-02-27 | $2.15M derived: sum of 3 quarters · filed 2025-02-27 | $1.21M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $642.00K derived: sum of 2 quarters · filed 2025-02-27 | -$295.00K derived: sum of 3 quarters · filed 2025-02-27 | -$2.94M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$509.00K 10-Q · filed 2023-11-08 | -$1.45M derived: sum of 2 quarters · filed 2023-11-08 | -$4.09M 10-Q · filed 2023-11-08 | -$4.85M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$937.00K 10-Q · filed 2023-08-07 | -$3.58M 10-Q · filed 2023-08-07 | -$4.34M derived: sum of 3 quarters · filed 2023-08-07 | -$4.35M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$2.65M 10-Q · filed 2023-05-09 | -$3.40M derived: sum of 2 quarters · filed 2023-05-09 | -$3.41M derived: sum of 3 quarters · filed 2023-05-09 | -$3.44M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$755.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$767.00K derived: sum of 2 quarters · filed 2023-03-27 | -$797.00K derived: sum of 3 quarters · filed 2023-03-27 | -$782.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | -$12.00K 10-Q · filed 2022-11-10 | -$42.00K derived: sum of 2 quarters · filed 2022-11-10 | -$27.00K 10-Q · filed 2022-11-10 | -$36.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$30.00K 10-Q · filed 2022-08-10 | -$15.00K 10-Q · filed 2022-08-10 | -$24.00K derived: sum of 3 quarters · filed 2022-08-10 | -$9.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $15.00K 10-Q · filed 2022-05-11 | $6.00K derived: sum of 2 quarters · filed 2022-05-11 | $21.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $6.00K derived: sum of 2 quarters · filed 2022-03-28 | $7.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $15.00K 10-Q · filed 2021-11-09 | $16.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |